Liver function tests profile in COVID-19 patients at the admission time: A systematic review of literature and conducted researches

Laali, Azadeh; Tabibzadeh, Alireza; Esghaei, Maryam; Yousefi, Parastoo; Soltani, Saber; Ajdarkosh, Hossein; Mosavi-Jarrahi, Alireza; Hadi Karbalaie Niya, Mohamad

Liver function tests profile in COVID-19 patients at the admission time: A systematic review of literature and conducted researches

Authors

¹ Department of Infectious Diseases, Firouzgar Hospital, Iran University of Medical Sciences, Tehran, Iran

² Department of Virology, Faculty of Medicine, Iran University of Medical Sciences, Tehran, Iran

³ Department of Virology, Faculty of Public Health, Tehran University of Medical Sciences, Tehran, Iran

⁴ Gastrointestinal and Liver Diseases Research Center, Iran University of Medical Sciences, Tehran, Iran

⁵ School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran

Abstract

Background: Since the start of coronavirus epidemic in Wuhan, China, in early December 2019, many literatures addressed its epidemiology, virology, and clinical presentation. In this review, we systematically reviewed the published literature in the field of liver function tests profile in COVID-19 patients at the admission time. Materials and Methods: systematic literature search were performed in EMBASE, PubMed, Science Direct, and Scopus using “severe acute respiratory syndrome 2 coronavirus (SARS-CoV-2)”, “SARS,” “SARS-CoV,” “coronavirus,” “novel coronavirus,” “liver,” “hepatitis,” “Liver function” keywords. The search was limited to range from 2019 to May 19, 2020. Results: From a total 7298 articles, 145 were screened and 18 were eligible for further analysis. The highest rate of liver associated comorbidities was reported 11%. The aspartate aminotransferase (AST) and alanine aminotransferase (ALT) were the most frequent assessed enzymes. Increase in AST level was seen in 10%–53% of patients while The ALT increase was seen in 5%–28% of COVID-19 patients at the admission time. The prothrombin time was increase in 7%–12% of patients and the D-dimer was reports increase in 14%–36% of COVID-19 patients at the admission time. Furthermore, albumin decrease was seen in 6%–98% of COVID-19 patients at the admission time. Conclusion: In conclusion, by using the results of study, it could be suggested that the liver function tests assessment is critical assessment in COVID-19 patients at the admission time. This liver function test could be used as potential prognostic factor in COVID-19 severity in future.

Keywords

References

1.	Lai MM, Cavanagh D. The molecular biology of coronaviruses. In: Advances in Virus Research. Vol. 48. Academic Press; 1997. p. 1-100.
2.	Wevers BA, van der Hoek L. Recently discovered human coronaviruses. Clin Lab Med 2009;29:715-24.
3.	Woo PC, Lau SK, Lam CS, Lau CC, Tsang AK, Lau JH, et al. Discovery of seven novel Mammalian and avian coronaviruses in the genus deltacoronavirus supports bat coronaviruses as the gene source of alphacoronavirus and betacoronavirus and avian coronaviruses as the gene source of gammacoronavirus and deltacoronavirus. J Virol 2012;86:3995-4008.
4.	Su S, Wong G, Shi W, Liu J, Lai ACK, Zhou J, et al. Epidemiology, genetic recombination, and pathogenesis of coronaviruses. Trends Microbiol 2016;24:490-502.
5.	Forni D, Cagliani R, Clerici M, Sironi M. Molecular evolution of human coronavirus genomes. Trends Microbiol 2017;25:35-48.
6.	Monto AS. Medical reviews. Coronaviruses. Yale J Biol Med 1974;47:234-51.
7.	Brian D, Baric R. Coronavirus genome structure and replication. Coronavirus replication and reverse genetics: Springer; 2005. p. 1-30.
8.	Lin CM, Saif LJ, Marthaler D, Wang Q. Evolution, antigenicity and pathogenicity of global porcine epidemic diarrhea virus strains. Virus Res 2016;226:20-39.
9.	Zhou P, Fan H, Lan T, Yang XL, Shi WF, Zhang W, et al. Fatal swine acute diarrhoea syndrome caused by an HKU2-related coronavirus of bat origin. Nature 2018;556:255-8.
10.	Huang YW, Dickerman AW, Piñeyro P, Li L, Fang L, Kiehne R, et al. Origin, evolution, and genotyping of emergent porcine epidemic diarrhea virus strains in the United States. mBio 2013;4:e00737-13.
11.	Liu C, Tang J, Ma Y, Liang X, Yang Y, Peng G, et al. Receptor usage and cell entry of porcine epidemic diarrhea coronavirus. J Virol 2015;89:6121-5.
12.	Simas PV, Barnabé AC, Durães-Carvalho R, Neto DF, Caserta LC, Artacho L, et al. Bat coronavirus in Brazil related to appalachian ridge and porcine epidemic diarrhea viruses. Emerg Infect Dis 2015;21:729-31.
13.	Lacroix A, Duong V, Hul V, San S, Davun H, Omaliss K, et al. Genetic diversity of coronaviruses in bats in Lao PDR and Cambodia. Infect Genet Evol 2017;48:10-8.
14.	Zhong N, Zheng B, Li Y, Poon L, Xie Z, Chan K, et al. Epidemiology and cause of severe acute respiratory syndrome (SARS) in Guangdong, People's Republic of China, in February, 2003. Lancet 2003;362:1353-8.
15.	Reusken CB, Haagmans BL, Müller MA, Gutierrez C, Godeke GJ, Meyer B, et al. Middle East respiratory syndrome coronavirus neutralising serum antibodies in dromedary camels: A comparative serological study. Lancet Infect Dis 2013;13:859-66.
16.	Guan Y, Zheng BJ, He YQ, Liu XL, Zhuang ZX, Cheung CL, et al. Isolation and characterization of viruses related to the SARS coronavirus from animals in southern China. Science 2003;302:276-8.
17.	Kan B, Wang M, Jing H, Xu H, Jiang X, Yan M, et al. Molecular evolution analysis and geographic investigation of severe acute respiratory syndrome coronavirus-like virus in palm civets at an animal market and on farms. J Virol 2005;79:11892-900.
18.	Tu C, Crameri G, Kong X, Chen J, Sun Y, Yu M, et al. Antibodies to SARS coronavirus in civets. Emerg Infect Dis 2004;10:2244-8.
19.	Song HD, Tu CC, Zhang GW, Wang SY, Zheng K, Lei LC, et al. Cross-host evolution of severe acute respiratory syndrome coronavirus in palm civet and human. Proc Natl Acad Sci U S A 2005;102:2430-5.
20.	Lau SK, Woo PC, Li KS, Huang Y, Tsoi HW, Wong BH, et al. Severe acute respiratory syndrome coronavirus-like virus in Chinese horseshoe bats. Proc Natl Acad Sci U S A 2005;102:14040-5.
21.	Yang L, Wu Z, Ren X, Yang F, He G, Zhang J, et al. Novel SARS-like betacoronaviruses in bats, China, 2011. Emerg Infect Dis 2013;19:989-91.
22.	He B, Zhang Y, Xu L, Yang W, Yang F, Feng Y, et al. Identification of diverse alphacoronaviruses and genomic characterization of a novel severe acute respiratory syndrome-like coronavirus from bats in China. J Virol 2014;88:7070-82.
23.	Jacob L, Smith L, Butler L, Barnett Y, Grabovac I, McDermott D, et al. COVID-19 social distancing and sexual activity in a sample of the British Public. J Sex Med 2020; 12:1229-36.
24.	Hernández A, Papadakos PJ, Torres A, González DA, Vives M, Ferrando C, et al. Dos terapias conocidas podrían ser efectivas como adyuvantes en el paciente crítico infectado por COVID-19. Rev Española de Anestesiol Reanimación 2020;67:245-52.
25.	Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 2020;395:497-506.
26.	Lomoro P, Verde F, Zerboni F, Simonetti I, Borghi C, Fachinetti C, et al. COVID-19 pneumonia manifestations at the admission on chest ultrasound, radiographs, and CT: Single-center study and comprehensive radiologic literature review. Eur J Radiol Open 2020;7:100231.
27.	Hui DS, I Azhar E, Madani TA, Ntoumi F, Kock R, Dar O, et al. The continuing 2019-nCoV epidemic threat of novel coronaviruses to global health-The latest 2019 novel coronavirus outbreak in Wuhan, China. Int J Infect Dis 2020;91:264-6.
28.	Cheng VC, Wong SC, To KK, Ho P, Yuen KY. Preparedness and proactive infection control measures against the emerging Wuhan coronavirus pneumonia in China. J Hospital Infect 2020;104(3):254-5.
29.	Peng S, Huang L, Zhao B, Zhou S, Braithwaite I, Zhang N, et al. Clinical course of coronavirus disease 2019 in 11 patients after thoracic surgery and challenges in diagnosis. J Thorac Cardiovasc Surg 2020;160:585-92.
30.	Turkistani KA. Precautions and recommendations for orthodontic settings during the COVID-19 outbreak: A review. Am J Orthod Dentofacial Orthop 2020.
31.	Fan Z, Chen L, Li J, Cheng X, Yang J, Tian C, et al. Clinical Features of COVID-19-Related Liver Damage. Clin Gastroenterol Hepatol 2020;18:1561-66.
32.	Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ, He JX, et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med 2020;382:1708-20.
33.	Zhou P, Yang XL, Wang XG, Hu B, Zhang L, Zhang W, et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature 2020;579:270-3.
34.	Chai X, Hu L, Zhang Y, Han W, Lu Z, Ke A, et al. Specific ACE2 expression in cholangiocytes may cause liver damage after 2019-nCoV infection. BioRxiv. 2020.
35.	Feng G, Zheng KI, Yan QQ, Rios RS, Targher G, Byrne CD, et al. COVID-19 and liver dysfunction: Current insights and emergent therapeutic strategies. J Clin Transl Hepatol 2020;8:18-24.
36.	Wang Y, Liu S, Liu H, Li W, Lin F, Jiang L, et al. SARS-CoV-2 infection of the liver directly contributes to hepatic impairment in patients with COVID-19. J Hepatol 2020.
37.	Cai Q, Huang D, Yu H, Zhu Z, Xia Z, Su Y, et al. COVID-19: Abnormal liver function tests. J Hepatol 2020;72:1864-72.
38.	Sun Y, Dong Y, Wang L, Xie H, Li B, Chang C, et al. Characteristics and prognostic factors of disease severity in patients with COVID-19: The Beijing experience. J Autoimmun 2020; Apr 24:102473.
39.	Zhang Y, Zheng L, Liu L, Zhao M, Xiao J, Zhao Q. Liver impairment in COVID-19 patients: A retrospective analysis of 115 cases from a single centre in Wuhan city, China. Liver Int 2020;40:2095-103.
40.	Pan L, Mu M, Yang P, Sun Y, Wang R, Yan J, et al. Clinical characteristics of COVID-19 patients with digestive symptoms in Hubei, China: A descriptive, cross-sectional, multicenter study. Am J Gastroenterol 2020;115:766-73.
41.	Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: A descriptive study. Lancet 2020;395:507-13.
42.	Xu XW, Wu XX, Jiang XG, Xu KJ, Ying LJ, Ma CL, et al. Clinical findings in a group of patients infected with the 2019 novel coronavirus (SARS-Cov-2) outside of Wuhan, China: Retrospective case series. BMJ 2020;368:???.
43.	Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: A retrospective cohort study. Lancet 2020;395:1054-62.
44.	Shi H, Han X, Jiang N, Cao Y, Alwalid O, Gu J, et al. Radiological findings from 81 patients with COVID-19 pneumonia in Wuhan, China: A descriptive study. Lancet Infect Dis 2020;20:425-34.
45.	Chen J, Qi T, Liu L, Ling Y, Qian Z, Li T, et al. Clinical progression of patients with COVID-19 in Shanghai, China. J Infect 2020;80:e1-e6.
46.	Huang Y, Tu M, Wang S, Chen S, Zhou W, Chen D, et al. Clinical characteristics of laboratory confirmed positive cases of SARS-CoV-2 infection in Wuhan, China: A retrospective single center analysis. Travel Med Infect Dis 2020;Feb 27:101606.
47.	Qian GQ, Yang NB, Ding F, Ma AHY, Wang ZY, Shen YF, et al. Epidemiologic and Clinical Characteristics of 91 Hospitalized Patients with COVID-19 in Zhejiang, China: A retrospective, multi-centre case series. QJM 2020;113:474-81.
48.	Yang W, Cao Q, Qin L, Wang X, Cheng Z, Pan A, et al. Clinical characteristics and imaging manifestations of the 2019 novel coronavirus disease (COVID-19): A multi-center study in Wenzhou city, Zhejiang, China. J Infect 2020;80:388-93.
49.	Wan S, Xiang Y, Fang W, Zheng Y, Li B, Hu Y, et al. Clinical features and treatment of COVID-19 patients in northeast Chongqing. J Med Virol 2020; 92: 797– 806.
50.	Jin X, Lian JS, Hu JH, Gao J, Zheng L, Zhang YM, et al. Epidemiological, clinical and virological characteristics of 74 cases of coronavirus-infected disease 2019 (COVID-19) with gastrointestinal symptoms. Gut 2020;69:1002-9.
51.	Mahony JB, Petrich A, Smieja M. Molecular diagnosis of respiratory virus infections. Crit Rev Clin Lab Sci 2011;48:217-49.
52.	Zhang N, Wang L, Deng X, Liang R, Su M, He C, et al. Recent advances in the detection of respiratory virus infection in humans. J Med Virol 2020;92:408-17.
53.	Azar MM, Landry ML. Detection of influenza A and B viruses and respiratory syncytial virus by use of clinical laboratory improvement amendments of 1988 (CLIA)-waived point-of-care assays: A paradigm shift to molecular tests. J Clin Microbiol 2018;56:e00367-18.
54.	Wang N, Luo C, Liu H, Yang X, Hu B, Zhang W, et al. Characterization of a new member of alphacoronavirus with unique genomic features in rhinolophus bats. Viruses 2019;11:379.
55.	Bhadra S, Jiang YS, Kumar MR, Johnson RF, Hensley LE, Ellington AD. Real-time sequence-validated loop-mediated isothermal amplification assays for detection of Middle East respiratory syndrome coronavirus (MERS-CoV). PLoS One 2015;10:e0123126.
56.	Chan JF, Choi GK, Tsang AK, Tee KM, Lam HY, Yip CC, et al. Development and evaluation of novel real-time reverse transcription-PCR assays with locked nucleic acid probes targeting leader sequences of human-pathogenic coronaviruses. J Clin Microbiol 2015;53:2722-6.
57.	Lu X, Whitaker B, Sakthivel SK, Kamili S, Rose LE, Lowe L, et al. Real-time reverse transcription-PCR assay panel for Middle East respiratory syndrome coronavirus. J Clin Microbiol 2014;52:67-75.
58.	Shirato K, Yano T, Senba S, Akachi S, Kobayashi T, Nishinaka T, et al. Detection of Middle East respiratory syndrome coronavirus using reverse transcription loop-mediated isothermal amplification (RT-LAMP). Virol J 2014;11:139.
59.	Shirato K, Semba S, El-Kafrawy SA, Hassan AM, Tolah AM, Takayama I, et al. Development of fluorescent reverse transcription loop-mediated isothermal amplification (RT-LAMP) using quenching probes for the detection of the Middle East respiratory syndrome coronavirus. J Virol Methods 2018;258:41-8.
60.	Corman VM, Eckerle I, Bleicker T, Zaki A, Landt O, Eschbach-Bludau M, et al. Detection of a novel human coronavirus by real-time reverse-transcription polymerase chain reaction. Euro Surveill 2012;17:20285.
61.	Abbott A. SARS testing: First past the post. Nature 2003;423:114.
62.	Corman VM, Müller MA, Costabel U, Timm J, Binger T, Meyer B, et al. Assays for laboratory confirmation of novel human coronavirus (hCoV-EMC) infections. Euro Surveill 2012;17:20334.
63.	Drosten C, Günther S, Preiser W, van der Werf S, Brodt HR, Becker S, et al. Identification of a novel coronavirus in patients with severe acute respiratory syndrome. N Engl J Med 2003;348:1967-76.
64.	Corman VM, Eickmann M, Landt O, Bleicker T, Brünink S, Eschbach-Bludau M, et al. Specific detection by real-time reverse-transcription PCR assays of a novel avian influenza A (H7N9) strain associated with human spillover infections in China. Euro Surveill 2013;18:20461.
65.	Panning M, Charrel RN, Donoso Mantke O, Landt O, Niedrig M, Drosten C. Coordinated implementation of chikungunya virus reverse transcription-PCR. Emerg Infect Dis 2009;15:469-71.
66.	Corman VM, Rasche A, Baronti C, Aldabbagh S, Cadar D, Reusken CB, et al. Assay optimization for molecular detection of Zika virus. Bulletin of the World Health Org 2016;94:880-92.
67.	Hsih WH, Cheng MY, Ho MW, Chou CH, Lin PC, Chi CY, et al. Featuring COVID-19 cases via screening symptomatic patients with epidemiologic link during flu season in a medical center of central Taiwan. J Microbiol Immunol Infect 2020;53:459-466.
68.	Peiris JS, Yuen KY, Osterhaus AD, Stöhr K. The severe acute respiratory syndrome. N Engl J Med 2003;349:2431-41.
69.	Ding Y, He L, Zhang Q, Huang Z, Che X, Hou J, et al. Organ distribution of severe acute respiratory syndrome (SARS) associated coronavirus (SARS-CoV) in SARS patients: Implications for pathogenesis and virus transmission pathways. J Pathol 2004;203:622-30.
70.	Hong HL, Kim SH, Choi DL, Kwon HH. A case of coronavirus disease 2019-infected liver transplant donor. Am J Transplant 2020;20:2938-41.
71.	Modjarrad K. Treatment strategies for Middle East respiratory syndrome coronavirus. J Virus Erad 2016;2:1-4.
72.	Behzadi MA, Leyva-Grado VH. Overview of current therapeutics and novel candidates against influenza, respiratory syncytial virus, and Middle East respiratory syndrome coronavirus infections. Front Microbiol 2019;10:1327.
73.	Zhang C, Wu Z, Li JW, Zhao H, Wang GQ. The cytokine release syndrome (CRS) of severe COVID-19 and Interleukin-6 receptor (IL-6R) antagonist Tocilizumab may be the key to reduce the mortality. Int J Antimicrob Agents 2020; Mar 29:105954.
74.	Al-Tawfiq JA, Momattin H, Dib J, Memish ZA. Ribavirin and interferon therapy in patients infected with the Middle East respiratory syndrome coronavirus: An observational study. Int J Infect Dis 2014;20:42-6.
75.	Al-Tawfiq JA, Memish ZA. Update on therapeutic options for Middle East Respiratory Syndrome Coronavirus (MERS-CoV). Expert Rev Anti Infect Ther 2017;15:269-75.
76.	Rabaan AA, Alahmed SH, Bazzi AM, Alhani HM. A review of candidate therapies for Middle East respiratory syndrome from a molecular perspective. J Med Microbiol 2017;66:1261-74.
77.	Rabaan AA. Middle East respiratory syndrome coronavirus: Five years later. Expert Rev Respir Med 2017;11:901-12.
78.	Soltani S, Zakeri AM, Karimi MR, Rezayat SA, Anbaji FZ, Tabibzadeh A, et al. A systematic literature review of current therapeutic approaches for COVID-19 patients. J Pharm Res Int 2020; May 18:13-25.

Advanced Biomedical Research